IQ EQ FUND MANAGEMENT IRELAND Ltd Has $927,000 Position in Henry Schein, Inc. (NASDAQ:HSIC)

IQ EQ FUND MANAGEMENT IRELAND Ltd trimmed its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 4.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,402 shares of the company’s stock after selling 639 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Henry Schein were worth $927,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Holocene Advisors LP acquired a new stake in Henry Schein during the 3rd quarter worth approximately $58,319,000. Southpoint Capital Advisors LP grew its stake in shares of Henry Schein by 30.0% in the third quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company’s stock worth $189,540,000 after purchasing an additional 600,000 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Henry Schein in the third quarter valued at $43,740,000. Bank of Montreal Can raised its position in Henry Schein by 365.6% during the 3rd quarter. Bank of Montreal Can now owns 711,487 shares of the company’s stock worth $52,095,000 after purchasing an additional 558,689 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Henry Schein during the 4th quarter worth about $34,720,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Stock Down 0.5 %

Shares of NASDAQ HSIC opened at $69.40 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The company has a 50-day moving average price of $74.71 and a 200-day moving average price of $72.60. The stock has a market capitalization of $8.62 billion, a P/E ratio of 28.56, a P/E/G ratio of 2.13 and a beta of 0.90. Henry Schein, Inc. has a 1 year low of $63.67 and a 1 year high of $82.49.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). The company had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. Henry Schein’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.66 EPS. On average, equities research analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Bradford C. Connett sold 4,036 shares of the business’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the transaction, the chief executive officer now directly owns 62,688 shares in the company, valued at approximately $4,460,251.20. The trade was a 6.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Philip A. Laskawy sold 2,604 shares of the stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total transaction of $184,988.16. Following the completion of the sale, the director now owns 24,805 shares of the company’s stock, valued at approximately $1,762,147.20. This trade represents a 9.50 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

HSIC has been the subject of several recent research reports. Bank of America raised Henry Schein from an “underperform” rating to a “buy” rating and increased their price target for the company from $69.00 to $84.00 in a research note on Monday, January 6th. Mizuho began coverage on Henry Schein in a research note on Wednesday, December 4th. They set a “neutral” rating and a $75.00 target price for the company. Jefferies Financial Group boosted their price target on Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Barrington Research reaffirmed an “outperform” rating and set a $90.00 price objective on shares of Henry Schein in a research report on Wednesday, February 26th. Finally, UBS Group dropped their target price on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 26th. Six investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $81.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.